Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:REGN News 3 December 2025 - 24 January 2026

Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

XLV fell 0.51% to $157.48 Friday, trailing the S&P 500, which ended flat. Health insurer CEOs faced House scrutiny over rising premiums and consolidation, with UnitedHealth pledging ACA rebates in 2026. UnitedHealth reports earnings Jan. 27, Regeneron on Jan. 30. Corcept Therapeutics jumped 45% after positive ovarian cancer trial results.
24 January 2026
·····
Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Published: December 4, 2025 Key Takeaways Wall Street Re‑rates Regeneron After Big Run — and Bigger Dupixent Story Regeneron Pharmaceuticals has suddenly become one of the most hotly debated large‑cap biotechs on Wall Street. On Thursday, December 4, 2025, multiple analyst moves and fresh data reshaped the Regeneron (REGN) stock narrative: Taken together, these moves signal that, despite a sharp rally off the summer lows, many professionals still see upside in REGN stock, driven primarily by Dupixent, Regeneron’s blockbuster anti‑inflammatory drug co‑developed with Sanofi, and a deepening pipeline in genetics and oncology. Investing.com+1 At the same time, concerns about valuation
4 December 2025
·
Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is ending 2025 in full “complex biotech” mode: the share price has rebounded, the dividend is now real, a flagship drug just got a powerful new label, a rare-disease medicine crushed a Phase 3 trial, and Wall Street is suddenly a bit less euphoric about the stock. On December 3, Morgan Stanley cut Regeneron from Overweight to Equal Weight with a $767 price target, arguing that the shares now more or less reflect fair value and that future upside will depend on how clearly the company can execute on its pipeline. MarketScreener+1 At the same
3 December 2025
··

Stock Market Today

GigaDevice Semiconductor stock price: What to watch for 603986 A-shares as memory crunch bites

GigaDevice Semiconductor stock price: What to watch for 603986 A-shares as memory crunch bites

8 February 2026
GigaDevice Semiconductor’s Class A shares closed at 276.17 yuan in Shanghai, down 0.6% Friday. The company faces a Feb. 11 shareholder vote on related-party transaction limits and an overseas auditor. Investors are watching for fallout from the global memory-chip shortage, which has pushed prices higher across the supply chain. GigaDevice’s shares have nearly doubled over the past year.
Astera Labs (ALAB) stock closes near $170 after 19% jump as earnings week looms

Astera Labs (ALAB) stock closes near $170 after 19% jump as earnings week looms

8 February 2026
Astera Labs shares jumped 18.9% to $169.85 Friday, trading as high as $170.01 on volume of 7.3 million. The move followed Amazon’s AI spending forecast and a nearly 6% gain in the PHLX Semiconductor Index. Astera reports fourth-quarter results Tuesday after market close, with revenue guidance at $245–$253 million.
Sungrow Power Supply (300274.SZ) A-shares: Monday watch after “commercial space” denial

Sungrow Power Supply (300274.SZ) A-shares: Monday watch after “commercial space” denial

8 February 2026
Sungrow closed at 144.50 yuan, down 1.03%, after stating it has no plans in the commercial space sector. Mainland China trading resumes Monday, with Spring Festival closures set for Feb. 15–23. Major funds were net sellers of 5.46 billion yuan on Feb. 6. The Shenzhen-listed solar firm remains under scrutiny as investors await further filings before the holiday.
MPWR stock price hits a new high after Monolithic Power’s outlook — what traders watch next week

MPWR stock price hits a new high after Monolithic Power’s outlook — what traders watch next week

8 February 2026
Monolithic Power Systems shares surged 6.4% to $1,229.82 Friday, hitting a new 52-week high after raising its dividend to $2.00 and forecasting first-quarter revenue of $770 million to $790 million. CEO Michael Hsing filed a Rule 144 notice for 3,082 shares. CFO Bernie Blegen will retire after the 2025 annual report, with Rob Dean named interim CFO. Fourth-quarter revenue rose 20.8% to $751.2 million.
Go toTop